HCPCS code J0593 — Inj., lanadelumab-flyo, 1 mg.
Status: Active.
Effective Jan 1, 2024.
Source: CMS HCPCS Level II.
J0593
ActiveInj., lanadelumab-flyo, 1 mg
Injection, lanadelumab-flyo, 1 mg (code may be used for medicare when drug administered under direct supervision of a physician, not for use when drug is self-administered)
Category:
Drugs
Section:
J-codes: Drugs Administered Other Than Oral Method
Effective:
Jan 1, 2024
Code type:
alphanumeric
OPPS Status:
K
— Non-pass-through drugs and biologicals
OPPS APC:
9326
MUE — Medically Unlikely Edits
Maximum units of J0593 Medicare will pay for one beneficiary on one date of service. Claims exceeding the MUE are denied or returned for review.
| Service Type | Max Units / Day |
|---|---|
| Outpatient Hospital | 300 |
| Practitioner Services | 300 |
Source: CMS Medicare NCCI Medically Unlikely Edits
NDC Crosswalk
National Drug Codes (NDCs) mapped to this HCPCS code.
| NDC | Drug Name |
|---|---|
| 47783-0644-01 | Takhzyro |
| 47783-0645-01 | Takhzyro |
| 47783-0646-01 | Takhzyro |
Change History
Quarterly changes published by CMS. Revisions may affect the code description, coverage, or rate — review each quarter's changes before submitting claims.
-
New Code 2024-Q1Inj., lanadelumab-flyo, 1 mg